ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Cwm LLC

Cwm LLC lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 114.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,192 shares of the biotechnology company’s stock after purchasing an additional 4,367 shares during the period. Cwm LLC’s holdings in ADMA Biologics were worth $92,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $31,000. Simplicity Wealth LLC purchased a new stake in ADMA Biologics during the first quarter worth $68,000. AJOVista LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $77,000. Oxford Asset Management LLP acquired a new stake in ADMA Biologics in the fourth quarter valued at $83,000. Finally, Viewpoint Capital Management LLC increased its position in shares of ADMA Biologics by 18.6% in the first quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 2,416 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Activity

In related news, CEO Adam S. Grossman sold 100,000 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the transaction, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $17.55 on Monday. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $17.87. The firm has a market cap of $4.07 billion, a price-to-earnings ratio of -877.50 and a beta of 0.55. The company’s 50-day moving average is $12.46 and its two-hundred day moving average is $8.81. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) earnings per share. Research analysts expect that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on ADMA. Mizuho boosted their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. HC Wainwright upped their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Cantor Fitzgerald increased their price target on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Finally, Raymond James lifted their price objective on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.